{"entity": "publication", "iuid": "9625c3c6b3564427ad033206aa5916ea", "timestamp": "2026-09-28T11:19:32.156Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/9625c3c6b3564427ad033206aa5916ea.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/9625c3c6b3564427ad033206aa5916ea"}}, "title": "Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer.", "authors": [{"family": "De Laere", "given": "Bram", "initials": "B"}, {"family": "Rajan", "given": "Prabhakar", "initials": "P"}, {"family": "Gr\u00f6nberg", "given": "Henrik", "initials": "H"}, {"family": "Dirix", "given": "Luc", "initials": "L"}, {"family": "Lindberg", "given": "Johan", "initials": "J"}, {"family": "CORE-ARV-CTC and ProBIO Investigators", "given": "", "initials": ""}], "type": "clinical trial", "published": "2019-07-01", "journal": {"title": "JAMA Oncol", "issn": "2374-2445", "volume": "5", "issue": "7", "pages": "1060-1062", "issn-l": null}, "abstract": "This post hoc analysis of a multi-institution cohort study assesses the association between androgen receptor perturbation and poorer outcome in patients with TP53 wild-type metastatic castration-resistant prostate cancer who are receiving abiraterone or enzalutamide.", "doi": "10.1001/jamaoncol.2019.0869", "pmid": "31046065", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6499126"}, {"db": "pii", "key": "2732501"}], "notes": [], "created": "2026-09-23T10:59:52.067Z", "modified": "2026-09-23T10:59:52.107Z"}